| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Esophageal Neoplasms | 35 | 2020 | 321 | 5.370 |
Why?
|
| Adenocarcinoma | 45 | 2021 | 1169 | 4.350 |
Why?
|
| Stomach Neoplasms | 21 | 2021 | 266 | 3.950 |
Why?
|
| Esophagectomy | 15 | 2019 | 84 | 2.930 |
Why?
|
| Liver Neoplasms | 24 | 2023 | 736 | 2.580 |
Why?
|
| Pancreatic Neoplasms | 22 | 2019 | 645 | 2.470 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 22 | 2023 | 2438 | 2.360 |
Why?
|
| Surgical Oncology | 4 | 2023 | 27 | 2.170 |
Why?
|
| Hepatectomy | 11 | 2014 | 166 | 2.140 |
Why?
|
| Colorectal Neoplasms | 20 | 2023 | 938 | 1.910 |
Why?
|
| Neoadjuvant Therapy | 12 | 2018 | 318 | 1.900 |
Why?
|
| Lymph Node Excision | 9 | 2016 | 217 | 1.750 |
Why?
|
| Pancreaticoduodenectomy | 9 | 2019 | 81 | 1.670 |
Why?
|
| Gastrectomy | 10 | 2021 | 68 | 1.530 |
Why?
|
| Carcinoma, Squamous Cell | 16 | 2017 | 1076 | 1.320 |
Why?
|
| General Surgery | 5 | 2016 | 229 | 1.310 |
Why?
|
| Medical Oncology | 5 | 2023 | 359 | 1.160 |
Why?
|
| Combined Modality Therapy | 32 | 2019 | 1686 | 1.140 |
Why?
|
| Humans | 195 | 2024 | 86643 | 1.080 |
Why?
|
| Head and Neck Neoplasms | 9 | 2019 | 1052 | 1.070 |
Why?
|
| Genetic Therapy | 13 | 2008 | 342 | 1.030 |
Why?
|
| Chemotherapy, Adjuvant | 13 | 2017 | 468 | 1.020 |
Why?
|
| Fellowships and Scholarships | 6 | 2020 | 108 | 0.920 |
Why?
|
| Human papillomavirus 16 | 2 | 2014 | 38 | 0.890 |
Why?
|
| Esophagogastric Junction | 2 | 2019 | 34 | 0.870 |
Why?
|
| Carcinoma | 6 | 2014 | 436 | 0.850 |
Why?
|
| Neoplasms | 19 | 2019 | 2898 | 0.790 |
Why?
|
| Middle Aged | 77 | 2023 | 25028 | 0.790 |
Why?
|
| MicroRNAs | 8 | 2023 | 534 | 0.790 |
Why?
|
| Tumor Necrosis Factor-alpha | 12 | 2012 | 683 | 0.770 |
Why?
|
| Aged | 69 | 2020 | 18415 | 0.760 |
Why?
|
| Male | 102 | 2023 | 40965 | 0.760 |
Why?
|
| Cholangiocarcinoma | 3 | 2014 | 66 | 0.750 |
Why?
|
| Laparoscopy | 8 | 2020 | 754 | 0.750 |
Why?
|
| Neoplasm Staging | 23 | 2019 | 1939 | 0.740 |
Why?
|
| Survival Rate | 19 | 2019 | 1863 | 0.740 |
Why?
|
| Female | 106 | 2023 | 44532 | 0.730 |
Why?
|
| Rectal Neoplasms | 4 | 2019 | 116 | 0.720 |
Why?
|
| Prognosis | 21 | 2022 | 3679 | 0.710 |
Why?
|
| Treatment Outcome | 36 | 2020 | 7993 | 0.700 |
Why?
|
| Neoplasm Metastasis | 12 | 2020 | 1056 | 0.670 |
Why?
|
| Metastasectomy | 2 | 2019 | 9 | 0.670 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2017 | 865 | 0.670 |
Why?
|
| Glucuronosyltransferase | 1 | 2020 | 184 | 0.660 |
Why?
|
| Antineoplastic Agents | 17 | 2020 | 2360 | 0.630 |
Why?
|
| Gene Expression Regulation, Neoplastic | 11 | 2018 | 1197 | 0.630 |
Why?
|
| Specialties, Surgical | 6 | 2020 | 64 | 0.610 |
Why?
|
| Awards and Prizes | 2 | 2013 | 36 | 0.570 |
Why?
|
| Bile Duct Neoplasms | 2 | 2014 | 79 | 0.560 |
Why?
|
| Fluorouracil | 12 | 2023 | 556 | 0.560 |
Why?
|
| Education, Medical, Graduate | 6 | 2018 | 369 | 0.560 |
Why?
|
| Gastrointestinal Stromal Tumors | 3 | 2012 | 23 | 0.550 |
Why?
|
| Lymph Nodes | 3 | 2016 | 533 | 0.550 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2016 | 35 | 0.550 |
Why?
|
| Follow-Up Studies | 18 | 2019 | 3640 | 0.540 |
Why?
|
| Immediate-Early Proteins | 5 | 2004 | 164 | 0.530 |
Why?
|
| Certification | 1 | 2015 | 58 | 0.520 |
Why?
|
| Digestive System Surgical Procedures | 5 | 2019 | 120 | 0.520 |
Why?
|
| Specialization | 1 | 2015 | 65 | 0.520 |
Why?
|
| Accreditation | 1 | 2015 | 60 | 0.520 |
Why?
|
| Surgical Procedures, Operative | 6 | 2019 | 182 | 0.510 |
Why?
|
| Pneumonia, Viral | 4 | 2020 | 316 | 0.510 |
Why?
|
| Coronavirus Infections | 4 | 2020 | 301 | 0.510 |
Why?
|
| Clinical Competence | 8 | 2018 | 751 | 0.500 |
Why?
|
| Comparative Effectiveness Research | 1 | 2015 | 53 | 0.490 |
Why?
|
| Pancreatectomy | 8 | 2019 | 148 | 0.490 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2004 | 384 | 0.490 |
Why?
|
| Neoplasm Recurrence, Local | 14 | 2019 | 1313 | 0.490 |
Why?
|
| Aged, 80 and over | 21 | 2020 | 6509 | 0.480 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2022 | 106 | 0.460 |
Why?
|
| Clinical Trials as Topic | 8 | 2020 | 1169 | 0.460 |
Why?
|
| Adult | 51 | 2020 | 25648 | 0.460 |
Why?
|
| Postoperative Complications | 8 | 2017 | 2207 | 0.450 |
Why?
|
| Thoracotomy | 2 | 2010 | 58 | 0.440 |
Why?
|
| Societies, Medical | 4 | 2019 | 572 | 0.430 |
Why?
|
| Biomarkers, Tumor | 5 | 2022 | 1464 | 0.420 |
Why?
|
| Pandemics | 5 | 2020 | 740 | 0.420 |
Why?
|
| Medical Records Systems, Computerized | 2 | 2011 | 40 | 0.410 |
Why?
|
| Disease Models, Animal | 9 | 2017 | 2232 | 0.410 |
Why?
|
| Sarcoma | 2 | 2012 | 215 | 0.410 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2011 | 31 | 0.400 |
Why?
|
| Prospective Studies | 15 | 2019 | 4213 | 0.400 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2011 | 34 | 0.400 |
Why?
|
| Forms and Records Control | 1 | 2011 | 16 | 0.400 |
Why?
|
| Xenograft Model Antitumor Assays | 11 | 2018 | 458 | 0.400 |
Why?
|
| Papillomavirus Infections | 1 | 2014 | 239 | 0.390 |
Why?
|
| Barrett Esophagus | 6 | 2014 | 93 | 0.380 |
Why?
|
| Liver Transplantation | 5 | 2016 | 1268 | 0.380 |
Why?
|
| Piperazines | 3 | 2012 | 272 | 0.370 |
Why?
|
| DNA-Binding Proteins | 7 | 2005 | 1208 | 0.370 |
Why?
|
| Proteome | 1 | 2011 | 124 | 0.370 |
Why?
|
| Cancer Vaccines | 2 | 2011 | 156 | 0.370 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 636 | 0.370 |
Why?
|
| Betacoronavirus | 4 | 2020 | 258 | 0.370 |
Why?
|
| Antibodies, Viral | 2 | 2011 | 293 | 0.360 |
Why?
|
| Radiotherapy | 7 | 2017 | 328 | 0.360 |
Why?
|
| Mice, Nude | 14 | 2020 | 790 | 0.360 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2011 | 118 | 0.350 |
Why?
|
| Pyrimidines | 3 | 2012 | 370 | 0.340 |
Why?
|
| Promoter Regions, Genetic | 9 | 2006 | 937 | 0.340 |
Why?
|
| Transcription Factors | 7 | 2005 | 1565 | 0.320 |
Why?
|
| Cisplatin | 13 | 2010 | 612 | 0.320 |
Why?
|
| Repressor Proteins | 1 | 2011 | 403 | 0.320 |
Why?
|
| Animals | 44 | 2020 | 26582 | 0.320 |
Why?
|
| Survival Analysis | 12 | 2017 | 1538 | 0.320 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2007 | 41 | 0.320 |
Why?
|
| Deoxycytidine | 3 | 2019 | 237 | 0.320 |
Why?
|
| Immunotherapy | 3 | 2016 | 629 | 0.320 |
Why?
|
| Glycolipids | 1 | 2007 | 29 | 0.310 |
Why?
|
| Postoperative Care | 5 | 2017 | 221 | 0.310 |
Why?
|
| Lung Neoplasms | 9 | 2019 | 2262 | 0.310 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2019 | 108 | 0.300 |
Why?
|
| Chemoradiotherapy | 5 | 2018 | 301 | 0.300 |
Why?
|
| Transcription, Genetic | 6 | 2009 | 1135 | 0.300 |
Why?
|
| Retrospective Studies | 18 | 2023 | 8489 | 0.300 |
Why?
|
| Chromosomes, Human, Pair 14 | 2 | 2018 | 49 | 0.300 |
Why?
|
| Induction Chemotherapy | 2 | 2018 | 147 | 0.290 |
Why?
|
| Disease-Free Survival | 8 | 2019 | 1204 | 0.290 |
Why?
|
| Rats, Inbred Strains | 1 | 2006 | 312 | 0.290 |
Why?
|
| Organoplatinum Compounds | 3 | 2017 | 94 | 0.280 |
Why?
|
| Glycoproteins | 1 | 2007 | 234 | 0.280 |
Why?
|
| Killer Cells, Natural | 2 | 1999 | 267 | 0.280 |
Why?
|
| Interpersonal Relations | 1 | 2007 | 170 | 0.280 |
Why?
|
| Consensus Development Conferences as Topic | 2 | 2016 | 28 | 0.280 |
Why?
|
| Lymphatic Metastasis | 6 | 2014 | 486 | 0.280 |
Why?
|
| Time Factors | 14 | 2017 | 5210 | 0.280 |
Why?
|
| Patient Selection | 4 | 2020 | 685 | 0.270 |
Why?
|
| Islets of Langerhans Transplantation | 2 | 2019 | 225 | 0.260 |
Why?
|
| Hospitals, Low-Volume | 2 | 2016 | 18 | 0.260 |
Why?
|
| Apoptosis | 8 | 2018 | 1683 | 0.260 |
Why?
|
| Tumor Cells, Cultured | 11 | 2018 | 1041 | 0.260 |
Why?
|
| Leucovorin | 4 | 2020 | 218 | 0.250 |
Why?
|
| HIV Envelope Protein gp120 | 8 | 2000 | 19 | 0.250 |
Why?
|
| Patient Dropouts | 1 | 2004 | 28 | 0.250 |
Why?
|
| Genetic Vectors | 8 | 2012 | 439 | 0.250 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2024 | 10 | 0.240 |
Why?
|
| Models, Animal | 2 | 2003 | 263 | 0.240 |
Why?
|
| Herpesvirus 1, Human | 4 | 2007 | 244 | 0.240 |
Why?
|
| Mice | 24 | 2020 | 11352 | 0.240 |
Why?
|
| Gastroenterology | 2 | 2016 | 134 | 0.240 |
Why?
|
| Neoplasm Transplantation | 9 | 2016 | 391 | 0.240 |
Why?
|
| Cell Line, Tumor | 15 | 2016 | 2426 | 0.240 |
Why?
|
| Quality Indicators, Health Care | 2 | 2016 | 144 | 0.230 |
Why?
|
| Laparotomy | 4 | 2015 | 59 | 0.230 |
Why?
|
| Waiting Lists | 1 | 2004 | 175 | 0.230 |
Why?
|
| Mucin-1 | 1 | 2003 | 44 | 0.220 |
Why?
|
| Oncolytic Virotherapy | 3 | 2007 | 41 | 0.220 |
Why?
|
| Stromal Cells | 1 | 2003 | 143 | 0.220 |
Why?
|
| Adenoviridae | 7 | 2007 | 345 | 0.220 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2010 | 292 | 0.220 |
Why?
|
| Internship and Residency | 4 | 2018 | 1004 | 0.220 |
Why?
|
| Peptide Fragments | 2 | 2003 | 460 | 0.220 |
Why?
|
| Endoscopy | 3 | 2014 | 332 | 0.210 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 930 | 0.210 |
Why?
|
| Transplantation, Heterotopic | 1 | 2002 | 45 | 0.210 |
Why?
|
| Early Growth Response Protein 1 | 8 | 2007 | 54 | 0.210 |
Why?
|
| Infection Control | 2 | 2020 | 115 | 0.210 |
Why?
|
| Abdominal Neoplasms | 1 | 2002 | 39 | 0.210 |
Why?
|
| Fibrosis | 1 | 2003 | 203 | 0.210 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2018 | 172 | 0.210 |
Why?
|
| Genes, p53 | 3 | 2001 | 109 | 0.210 |
Why?
|
| Esophagoscopy | 2 | 2014 | 87 | 0.210 |
Why?
|
| Biological Products | 1 | 2024 | 143 | 0.200 |
Why?
|
| HIV-1 | 7 | 2000 | 163 | 0.200 |
Why?
|
| Melanoma | 2 | 1996 | 459 | 0.200 |
Why?
|
| Circulating Tumor DNA | 1 | 2022 | 37 | 0.200 |
Why?
|
| User-Computer Interface | 2 | 2020 | 185 | 0.200 |
Why?
|
| Biopsy, Needle | 6 | 2010 | 235 | 0.200 |
Why?
|
| Genotype | 4 | 2020 | 1851 | 0.200 |
Why?
|
| Mouth Neoplasms | 3 | 2015 | 194 | 0.200 |
Why?
|
| Melanoma, Experimental | 3 | 2011 | 103 | 0.190 |
Why?
|
| Colonic Neoplasms | 4 | 2003 | 556 | 0.190 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2018 | 592 | 0.190 |
Why?
|
| Vaccination | 2 | 2016 | 254 | 0.190 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2022 | 71 | 0.190 |
Why?
|
| Acetophenones | 1 | 2020 | 27 | 0.190 |
Why?
|
| Kidney Transplantation | 2 | 2011 | 849 | 0.190 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2000 | 33 | 0.190 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2019 | 2601 | 0.190 |
Why?
|
| Breast Neoplasms | 7 | 2015 | 2903 | 0.190 |
Why?
|
| Recurrence | 2 | 2014 | 1139 | 0.190 |
Why?
|
| Imatinib Mesylate | 3 | 2012 | 126 | 0.190 |
Why?
|
| United States | 12 | 2019 | 6672 | 0.190 |
Why?
|
| Adoptive Transfer | 2 | 1999 | 168 | 0.180 |
Why?
|
| Transplantation Tolerance | 1 | 2002 | 130 | 0.180 |
Why?
|
| Neoplasms, Experimental | 4 | 2016 | 269 | 0.180 |
Why?
|
| Actomyosin | 1 | 2020 | 46 | 0.180 |
Why?
|
| Pneumonectomy | 1 | 2002 | 196 | 0.180 |
Why?
|
| Positron-Emission Tomography | 2 | 2020 | 329 | 0.180 |
Why?
|
| Surgery Department, Hospital | 1 | 2020 | 42 | 0.180 |
Why?
|
| Hypothyroidism | 1 | 2001 | 232 | 0.180 |
Why?
|
| Mutation | 7 | 2018 | 3968 | 0.180 |
Why?
|
| Rats | 10 | 2007 | 3990 | 0.180 |
Why?
|
| Personnel Selection | 1 | 2020 | 59 | 0.180 |
Why?
|
| HCT116 Cells | 5 | 2020 | 151 | 0.180 |
Why?
|
| History, 20th Century | 2 | 2013 | 312 | 0.180 |
Why?
|
| Biliary Tract Surgical Procedures | 2 | 2016 | 11 | 0.180 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2019 | 90 | 0.180 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 57 | 0.180 |
Why?
|
| Benzamides | 3 | 2012 | 229 | 0.180 |
Why?
|
| Health Resources | 1 | 2020 | 76 | 0.180 |
Why?
|
| Income | 1 | 2019 | 75 | 0.170 |
Why?
|
| Internet | 3 | 2020 | 312 | 0.170 |
Why?
|
| Cytoskeleton | 1 | 2020 | 193 | 0.170 |
Why?
|
| Guidelines as Topic | 2 | 2018 | 162 | 0.170 |
Why?
|
| Interviews as Topic | 1 | 2020 | 319 | 0.170 |
Why?
|
| Liver Diseases | 1 | 2001 | 238 | 0.170 |
Why?
|
| B7-H1 Antigen | 2 | 2018 | 250 | 0.170 |
Why?
|
| Colectomy | 1 | 2000 | 167 | 0.170 |
Why?
|
| Cytokines | 2 | 2002 | 776 | 0.170 |
Why?
|
| Minimally Invasive Surgical Procedures | 3 | 2012 | 237 | 0.160 |
Why?
|
| Immunohistochemistry | 7 | 2012 | 1753 | 0.160 |
Why?
|
| Palliative Medicine | 1 | 2018 | 11 | 0.160 |
Why?
|
| Hospitals | 3 | 2019 | 294 | 0.160 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 185 | 0.160 |
Why?
|
| Risk Assessment | 5 | 2014 | 2261 | 0.160 |
Why?
|
| Manuscripts as Topic | 1 | 2018 | 4 | 0.160 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 1998 | 12 | 0.160 |
Why?
|
| Writing | 1 | 2018 | 29 | 0.160 |
Why?
|
| Residence Characteristics | 1 | 2019 | 197 | 0.160 |
Why?
|
| Gene Amplification | 1 | 2018 | 131 | 0.160 |
Why?
|
| Precancerous Conditions | 2 | 2009 | 196 | 0.160 |
Why?
|
| Janus Kinase 2 | 1 | 2018 | 57 | 0.160 |
Why?
|
| Perioperative Care | 1 | 2019 | 161 | 0.160 |
Why?
|
| Parenteral Nutrition | 1 | 1998 | 60 | 0.160 |
Why?
|
| Pyrrolidines | 1 | 2018 | 58 | 0.150 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2003 | 80 | 0.150 |
Why?
|
| Transplantation, Heterologous | 4 | 2003 | 363 | 0.150 |
Why?
|
| Thinness | 1 | 2017 | 43 | 0.150 |
Why?
|
| Radiation, Ionizing | 6 | 2011 | 121 | 0.150 |
Why?
|
| Publishing | 1 | 2018 | 90 | 0.150 |
Why?
|
| Chicago | 5 | 2020 | 1379 | 0.150 |
Why?
|
| Nitric Oxide Synthase | 1 | 1997 | 125 | 0.150 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2017 | 176 | 0.140 |
Why?
|
| Journal Impact Factor | 1 | 2016 | 15 | 0.140 |
Why?
|
| DNA | 5 | 2012 | 1294 | 0.140 |
Why?
|
| Nanostructures | 1 | 2017 | 77 | 0.140 |
Why?
|
| Interleukin-2 | 1 | 1997 | 249 | 0.140 |
Why?
|
| Hospitals, High-Volume | 1 | 2016 | 35 | 0.140 |
Why?
|
| Benchmarking | 1 | 2016 | 78 | 0.140 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 1995 | 18 | 0.140 |
Why?
|
| Sulfonamides | 1 | 2018 | 300 | 0.140 |
Why?
|
| Chemokine CXCL10 | 1 | 2015 | 17 | 0.130 |
Why?
|
| Tissue Preservation | 1 | 2015 | 14 | 0.130 |
Why?
|
| Surgeons | 1 | 2019 | 238 | 0.130 |
Why?
|
| DNA Methylation | 2 | 2018 | 628 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 6 | 2014 | 1376 | 0.130 |
Why?
|
| Pancreatic Fistula | 1 | 2015 | 16 | 0.130 |
Why?
|
| Octreotide | 1 | 2015 | 16 | 0.130 |
Why?
|
| Disease Progression | 5 | 2012 | 1531 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2018 | 589 | 0.130 |
Why?
|
| Viral Proteins | 2 | 2007 | 300 | 0.130 |
Why?
|
| Hyperthermia, Induced | 1 | 1995 | 73 | 0.130 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 371 | 0.130 |
Why?
|
| Quality Improvement | 2 | 2016 | 428 | 0.130 |
Why?
|
| Diagnostic Imaging | 3 | 2015 | 469 | 0.130 |
Why?
|
| Skin Neoplasms | 2 | 2019 | 546 | 0.130 |
Why?
|
| Signal Transduction | 5 | 2024 | 3241 | 0.130 |
Why?
|
| Hepatitis C | 1 | 1997 | 208 | 0.130 |
Why?
|
| Pancreatitis, Chronic | 1 | 2015 | 49 | 0.130 |
Why?
|
| Drug Therapy | 1 | 2015 | 70 | 0.120 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2007 | 381 | 0.120 |
Why?
|
| Teaching | 2 | 2013 | 147 | 0.120 |
Why?
|
| Decision Making | 1 | 2020 | 642 | 0.120 |
Why?
|
| Self Care | 1 | 2015 | 164 | 0.120 |
Why?
|
| Dissent and Disputes | 1 | 2014 | 28 | 0.120 |
Why?
|
| Registries | 2 | 2015 | 702 | 0.120 |
Why?
|
| Pursuit, Smooth | 1 | 1994 | 31 | 0.120 |
Why?
|
| Universities | 1 | 2015 | 135 | 0.120 |
Why?
|
| Graft Rejection | 3 | 2011 | 1065 | 0.120 |
Why?
|
| Cohort Studies | 6 | 2017 | 2767 | 0.120 |
Why?
|
| Cholangitis | 2 | 2012 | 19 | 0.120 |
Why?
|
| Periodicals as Topic | 1 | 2016 | 168 | 0.120 |
Why?
|
| Pediatrics | 1 | 2018 | 344 | 0.120 |
Why?
|
| Referral and Consultation | 1 | 2016 | 328 | 0.120 |
Why?
|
| Cetuximab | 1 | 2014 | 113 | 0.120 |
Why?
|
| CD4 Antigens | 5 | 2000 | 83 | 0.120 |
Why?
|
| Body Mass Index | 1 | 2017 | 770 | 0.120 |
Why?
|
| Biomedical Research | 1 | 2018 | 376 | 0.120 |
Why?
|
| Critical Care | 1 | 2016 | 370 | 0.120 |
Why?
|
| Data Collection | 1 | 2015 | 372 | 0.120 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2018 | 1075 | 0.120 |
Why?
|
| Peritoneal Lavage | 1 | 2013 | 10 | 0.120 |
Why?
|
| SEER Program | 1 | 2014 | 190 | 0.110 |
Why?
|
| Length of Stay | 5 | 2017 | 702 | 0.110 |
Why?
|
| Precision Medicine | 1 | 2017 | 395 | 0.110 |
Why?
|
| Mastectomy, Segmental | 1 | 1994 | 93 | 0.110 |
Why?
|
| Incidence | 6 | 2014 | 1577 | 0.110 |
Why?
|
| Preoperative Care | 3 | 2017 | 397 | 0.110 |
Why?
|
| History, 21st Century | 1 | 2013 | 175 | 0.110 |
Why?
|
| Program Evaluation | 3 | 2020 | 297 | 0.110 |
Why?
|
| Lung | 5 | 2012 | 1170 | 0.110 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2011 | 376 | 0.110 |
Why?
|
| Geriatric Assessment | 1 | 2014 | 166 | 0.110 |
Why?
|
| Receptor, EphB4 | 1 | 2012 | 24 | 0.110 |
Why?
|
| Cues | 1 | 1994 | 175 | 0.110 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2016 | 383 | 0.110 |
Why?
|
| Interferon-alpha | 3 | 2010 | 233 | 0.110 |
Why?
|
| Sequence Deletion | 3 | 2007 | 205 | 0.110 |
Why?
|
| Portraits as Topic | 1 | 2012 | 6 | 0.110 |
Why?
|
| Heterografts | 3 | 2018 | 98 | 0.110 |
Why?
|
| Genomics | 1 | 2017 | 720 | 0.100 |
Why?
|
| Carcinoma, Lobular | 1 | 2012 | 81 | 0.100 |
Why?
|
| Cadherins | 1 | 2012 | 151 | 0.100 |
Why?
|
| Leadership | 1 | 2013 | 134 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2016 | 559 | 0.100 |
Why?
|
| Carcinoma in Situ | 1 | 1992 | 53 | 0.100 |
Why?
|
| Adolescent | 11 | 2017 | 8981 | 0.100 |
Why?
|
| Islets of Langerhans | 1 | 2015 | 544 | 0.100 |
Why?
|
| Databases, Factual | 4 | 2019 | 814 | 0.100 |
Why?
|
| Patient Care Team | 1 | 2014 | 280 | 0.100 |
Why?
|
| Hemangioma, Cavernous | 1 | 1992 | 69 | 0.100 |
Why?
|
| Remission Induction | 4 | 2001 | 722 | 0.100 |
Why?
|
| Faculty, Medical | 1 | 2013 | 178 | 0.100 |
Why?
|
| Maximum Tolerated Dose | 1 | 2012 | 270 | 0.100 |
Why?
|
| Intraoperative Period | 1 | 2011 | 90 | 0.100 |
Why?
|
| Urine | 1 | 2011 | 90 | 0.100 |
Why?
|
| Capecitabine | 1 | 2011 | 96 | 0.100 |
Why?
|
| Research Design | 2 | 2013 | 594 | 0.100 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 1992 | 113 | 0.100 |
Why?
|
| MAP Kinase Kinase Kinases | 2 | 2007 | 41 | 0.100 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2011 | 72 | 0.100 |
Why?
|
| Educational Measurement | 2 | 2009 | 225 | 0.100 |
Why?
|
| Oxidoreductases | 1 | 2011 | 112 | 0.100 |
Why?
|
| Bile Ducts, Extrahepatic | 1 | 2010 | 12 | 0.090 |
Why?
|
| Virus Replication | 4 | 2007 | 319 | 0.090 |
Why?
|
| Neoplasm, Residual | 2 | 2015 | 162 | 0.090 |
Why?
|
| Obesity | 1 | 2017 | 963 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2011 | 689 | 0.090 |
Why?
|
| Drug Administration Schedule | 4 | 2017 | 916 | 0.090 |
Why?
|
| Benzimidazoles | 1 | 2011 | 140 | 0.090 |
Why?
|
| Cholestasis | 1 | 1990 | 47 | 0.090 |
Why?
|
| Immunologic Memory | 1 | 2011 | 152 | 0.090 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2011 | 123 | 0.090 |
Why?
|
| HIV Antibodies | 3 | 1995 | 25 | 0.090 |
Why?
|
| DNA Damage | 3 | 2011 | 366 | 0.090 |
Why?
|
| Digestive System Neoplasms | 1 | 2009 | 20 | 0.090 |
Why?
|
| Triage | 2 | 2020 | 108 | 0.090 |
Why?
|
| STAT1 Transcription Factor | 1 | 2009 | 52 | 0.090 |
Why?
|
| Neuroendocrine Tumors | 1 | 2011 | 105 | 0.090 |
Why?
|
| X-Ray Therapy | 1 | 2008 | 6 | 0.090 |
Why?
|
| Fibroma | 1 | 1989 | 33 | 0.080 |
Why?
|
| Feedback | 1 | 2009 | 133 | 0.080 |
Why?
|
| Transforming Growth Factor beta | 1 | 2011 | 301 | 0.080 |
Why?
|
| Membrane Glycoproteins | 1 | 2011 | 428 | 0.080 |
Why?
|
| Treatment Failure | 3 | 2012 | 285 | 0.080 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2008 | 94 | 0.080 |
Why?
|
| Genetic Testing | 1 | 2012 | 535 | 0.080 |
Why?
|
| Thoracoscopy | 3 | 1998 | 22 | 0.080 |
Why?
|
| Stilbenes | 1 | 2007 | 25 | 0.080 |
Why?
|
| Enzyme Inhibitors | 1 | 2011 | 639 | 0.080 |
Why?
|
| Interleukin-4 | 2 | 2002 | 127 | 0.080 |
Why?
|
| Lipid Droplets | 1 | 2007 | 16 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 5 | 2016 | 3092 | 0.080 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2007 | 44 | 0.080 |
Why?
|
| Doxorubicin | 2 | 2009 | 295 | 0.080 |
Why?
|
| Child | 9 | 2018 | 6927 | 0.080 |
Why?
|
| Epitopes | 5 | 2000 | 255 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2007 | 79 | 0.080 |
Why?
|
| Gene Expression Profiling | 4 | 2018 | 1384 | 0.080 |
Why?
|
| Adenoviruses, Human | 2 | 2012 | 41 | 0.080 |
Why?
|
| Necrosis | 2 | 2007 | 204 | 0.080 |
Why?
|
| Hypercalcemia | 1 | 2007 | 59 | 0.080 |
Why?
|
| Ethics, Medical | 1 | 2010 | 306 | 0.070 |
Why?
|
| Parathyroid Neoplasms | 1 | 2007 | 55 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2021 | 860 | 0.070 |
Why?
|
| Immunity, Cellular | 1 | 2007 | 177 | 0.070 |
Why?
|
| Common Bile Duct | 2 | 1991 | 19 | 0.070 |
Why?
|
| Blood Cells | 1 | 2006 | 33 | 0.070 |
Why?
|
| Veratrum Alkaloids | 1 | 2006 | 9 | 0.070 |
Why?
|
| Cell Movement | 3 | 2020 | 758 | 0.070 |
Why?
|
| Transplantation, Autologous | 2 | 2019 | 331 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2012 | 2271 | 0.070 |
Why?
|
| Infusions, Intravenous | 5 | 1995 | 429 | 0.070 |
Why?
|
| Paclitaxel | 2 | 2006 | 460 | 0.070 |
Why?
|
| Luminescent Proteins | 2 | 2004 | 144 | 0.070 |
Why?
|
| eIF-2 Kinase | 1 | 2006 | 46 | 0.070 |
Why?
|
| Drug Synergism | 3 | 2017 | 303 | 0.070 |
Why?
|
| Gene Expression | 4 | 2015 | 1284 | 0.070 |
Why?
|
| Gallbladder | 1 | 1985 | 30 | 0.070 |
Why?
|
| Hedgehog Proteins | 1 | 2006 | 93 | 0.070 |
Why?
|
| Endothelium, Vascular | 3 | 2004 | 435 | 0.070 |
Why?
|
| Neutralization Tests | 6 | 2001 | 77 | 0.070 |
Why?
|
| Green Fluorescent Proteins | 2 | 2004 | 305 | 0.070 |
Why?
|
| Endothelial Cells | 2 | 2008 | 428 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2006 | 101 | 0.070 |
Why?
|
| Mice, SCID | 2 | 2016 | 252 | 0.070 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2005 | 125 | 0.070 |
Why?
|
| Rats, Inbred F344 | 3 | 1997 | 156 | 0.070 |
Why?
|
| Spleen | 1 | 2006 | 430 | 0.070 |
Why?
|
| Congresses as Topic | 2 | 2016 | 116 | 0.070 |
Why?
|
| Models, Biological | 4 | 2006 | 1749 | 0.060 |
Why?
|
| Glycine | 1 | 2005 | 92 | 0.060 |
Why?
|
| Transplantation, Homologous | 2 | 2011 | 996 | 0.060 |
Why?
|
| Camptothecin | 2 | 2017 | 189 | 0.060 |
Why?
|
| Ethiodized Oil | 1 | 2004 | 1 | 0.060 |
Why?
|
| Polyethylene Glycols | 2 | 2017 | 363 | 0.060 |
Why?
|
| Cyclophosphamide | 1 | 2005 | 299 | 0.060 |
Why?
|
| Pilot Projects | 3 | 2017 | 839 | 0.060 |
Why?
|
| Cytotoxins | 1 | 2004 | 15 | 0.060 |
Why?
|
| NF-kappa B | 1 | 2007 | 444 | 0.060 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2004 | 36 | 0.060 |
Why?
|
| Adjuvants, Immunologic | 1 | 2005 | 167 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2011 | 2705 | 0.060 |
Why?
|
| Logistic Models | 2 | 2019 | 1186 | 0.060 |
Why?
|
| Transfection | 6 | 2007 | 896 | 0.060 |
Why?
|
| Body Weight | 3 | 2017 | 459 | 0.060 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2004 | 114 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2018 | 407 | 0.060 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 1996 | 100 | 0.060 |
Why?
|
| Young Adult | 4 | 2017 | 5976 | 0.060 |
Why?
|
| Internationality | 2 | 2014 | 69 | 0.060 |
Why?
|
| Behavior, Animal | 1 | 2006 | 373 | 0.060 |
Why?
|
| Needs Assessment | 2 | 2015 | 154 | 0.060 |
Why?
|
| HIV Seropositivity | 2 | 1995 | 49 | 0.060 |
Why?
|
| Cell Adhesion | 2 | 2020 | 420 | 0.060 |
Why?
|
| Staining and Labeling | 1 | 2003 | 165 | 0.060 |
Why?
|
| Etoposide | 4 | 2007 | 196 | 0.060 |
Why?
|
| Mitosis | 1 | 2003 | 153 | 0.060 |
Why?
|
| Erythropoietin | 1 | 2003 | 91 | 0.050 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2005 | 427 | 0.050 |
Why?
|
| Mortality | 1 | 2003 | 149 | 0.050 |
Why?
|
| Random Allocation | 1 | 2003 | 332 | 0.050 |
Why?
|
| External Fixators | 2 | 1992 | 19 | 0.050 |
Why?
|
| Aortic Diseases | 2 | 1994 | 100 | 0.050 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2002 | 118 | 0.050 |
Why?
|
| Rats, Inbred ACI | 1 | 2002 | 25 | 0.050 |
Why?
|
| beta Catenin | 1 | 2024 | 251 | 0.050 |
Why?
|
| Transplantation, Isogeneic | 1 | 2002 | 39 | 0.050 |
Why?
|
| Tumor Burden | 2 | 2015 | 289 | 0.050 |
Why?
|
| Liver Cirrhosis | 1 | 2004 | 297 | 0.050 |
Why?
|
| Catheter Ablation | 1 | 2004 | 233 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2010 | 1565 | 0.050 |
Why?
|
| Ethanol | 1 | 2004 | 249 | 0.050 |
Why?
|
| Endothelial Growth Factors | 1 | 2002 | 55 | 0.050 |
Why?
|
| Rats, Inbred Lew | 1 | 2002 | 186 | 0.050 |
Why?
|
| Lymphokines | 1 | 2002 | 76 | 0.050 |
Why?
|
| Glioblastoma | 1 | 2004 | 255 | 0.050 |
Why?
|
| Prostatic Neoplasms | 2 | 2011 | 1721 | 0.050 |
Why?
|
| Risk Factors | 4 | 2017 | 5417 | 0.050 |
Why?
|
| Drug Evaluation | 2 | 1992 | 141 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2001 | 912 | 0.050 |
Why?
|
| Guanine | 1 | 2002 | 208 | 0.050 |
Why?
|
| Up-Regulation | 4 | 2005 | 712 | 0.050 |
Why?
|
| Focal Nodular Hyperplasia | 1 | 2001 | 9 | 0.050 |
Why?
|
| Coumarins | 1 | 2000 | 13 | 0.050 |
Why?
|
| Recombinant Proteins | 2 | 2010 | 1014 | 0.050 |
Why?
|
| Interleukin-10 | 1 | 2002 | 149 | 0.050 |
Why?
|
| Thyrotropin | 2 | 2001 | 280 | 0.050 |
Why?
|
| Receptors, Chemokine | 1 | 2000 | 31 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2012 | 273 | 0.050 |
Why?
|
| Hamartoma | 1 | 2001 | 31 | 0.050 |
Why?
|
| Hemangioma | 1 | 2001 | 60 | 0.050 |
Why?
|
| Cell Proliferation | 2 | 2018 | 1578 | 0.050 |
Why?
|
| Blood Loss, Surgical | 1 | 2001 | 112 | 0.050 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2021 | 73 | 0.050 |
Why?
|
| Illinois | 2 | 2014 | 462 | 0.050 |
Why?
|
| Biomarkers | 3 | 2003 | 1718 | 0.050 |
Why?
|
| Patient Readmission | 2 | 2014 | 329 | 0.050 |
Why?
|
| Polysaccharides | 1 | 2000 | 89 | 0.050 |
Why?
|
| Organizational Innovation | 1 | 2020 | 41 | 0.050 |
Why?
|
| Phenotype | 3 | 2015 | 2378 | 0.050 |
Why?
|
| Cysts | 1 | 2001 | 104 | 0.050 |
Why?
|
| Mice, Transgenic | 2 | 2016 | 1540 | 0.050 |
Why?
|
| Efficiency, Organizational | 1 | 2020 | 58 | 0.050 |
Why?
|
| Spinal Nerve Roots | 1 | 1999 | 17 | 0.050 |
Why?
|
| Ampulla of Vater | 1 | 2019 | 22 | 0.040 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 1999 | 19 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2001 | 678 | 0.040 |
Why?
|
| Neurilemmoma | 1 | 1999 | 34 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 3 | 2005 | 552 | 0.040 |
Why?
|
| Healthy Lifestyle | 1 | 2019 | 9 | 0.040 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 1999 | 43 | 0.040 |
Why?
|
| Rats, Nude | 1 | 1999 | 22 | 0.040 |
Why?
|
| Genes, env | 3 | 1993 | 8 | 0.040 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2018 | 18 | 0.040 |
Why?
|
| Pathology, Molecular | 1 | 2019 | 34 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2014 | 1673 | 0.040 |
Why?
|
| Cell Survival | 3 | 2007 | 969 | 0.040 |
Why?
|
| Child, Preschool | 4 | 2001 | 3612 | 0.040 |
Why?
|
| Adenoma | 1 | 2001 | 235 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2018 | 106 | 0.040 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2018 | 55 | 0.040 |
Why?
|
| Feasibility Studies | 3 | 2013 | 751 | 0.040 |
Why?
|
| Equivalence Trials as Topic | 1 | 2018 | 5 | 0.040 |
Why?
|
| Keratinocytes | 1 | 1999 | 143 | 0.040 |
Why?
|
| Class II Phosphatidylinositol 3-Kinases | 1 | 2018 | 8 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 266 | 0.040 |
Why?
|
| Primary Prevention | 1 | 2019 | 85 | 0.040 |
Why?
|
| Training Support | 1 | 2018 | 23 | 0.040 |
Why?
|
| Interdisciplinary Studies | 1 | 2018 | 20 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 674 | 0.040 |
Why?
|
| Perfusion | 1 | 1999 | 203 | 0.040 |
Why?
|
| Mutagenesis, Site-Directed | 3 | 1993 | 279 | 0.040 |
Why?
|
| Medical Staff, Hospital | 2 | 2009 | 107 | 0.040 |
Why?
|
| Laryngectomy | 1 | 2018 | 26 | 0.040 |
Why?
|
| Anorexia | 2 | 2013 | 30 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2002 | 532 | 0.040 |
Why?
|
| Nutrition Disorders | 1 | 1998 | 16 | 0.040 |
Why?
|
| Azacitidine | 1 | 2018 | 137 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 236 | 0.040 |
Why?
|
| Thoracic Neoplasms | 1 | 1998 | 64 | 0.040 |
Why?
|
| Filgrastim | 1 | 2017 | 56 | 0.040 |
Why?
|
| Receptor, Notch1 | 1 | 2018 | 85 | 0.040 |
Why?
|
| Injections, Intralesional | 2 | 2012 | 22 | 0.040 |
Why?
|
| Oxygen | 1 | 2003 | 726 | 0.040 |
Why?
|
| Pregnancy Complications | 1 | 2001 | 336 | 0.040 |
Why?
|
| RNA, Long Noncoding | 1 | 2018 | 102 | 0.040 |
Why?
|
| Dihydroxyphenylalanine | 1 | 2017 | 13 | 0.040 |
Why?
|
| Point Mutation | 1 | 1998 | 246 | 0.040 |
Why?
|
| HIV Envelope Protein gp41 | 2 | 1994 | 3 | 0.040 |
Why?
|
| Reoperation | 3 | 2014 | 597 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2006 | 1961 | 0.040 |
Why?
|
| Enzyme Induction | 1 | 1997 | 88 | 0.040 |
Why?
|
| Actins | 1 | 2020 | 451 | 0.040 |
Why?
|
| Radiotherapy Dosage | 1 | 1998 | 468 | 0.040 |
Why?
|
| Cyclins | 1 | 1997 | 82 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 1997 | 74 | 0.040 |
Why?
|
| Algorithms | 2 | 2006 | 1830 | 0.040 |
Why?
|
| Carcinoma, Lewis Lung | 2 | 2011 | 23 | 0.040 |
Why?
|
| cdc25 Phosphatases | 1 | 2016 | 18 | 0.040 |
Why?
|
| Professional Autonomy | 1 | 2016 | 41 | 0.040 |
Why?
|
| Safety | 2 | 2013 | 152 | 0.040 |
Why?
|
| Kidney Neoplasms | 2 | 2002 | 621 | 0.040 |
Why?
|
| Drug Carriers | 1 | 2017 | 81 | 0.040 |
Why?
|
| ErbB Receptors | 1 | 1999 | 485 | 0.040 |
Why?
|
| Overweight | 1 | 2017 | 118 | 0.030 |
Why?
|
| Pancreaticojejunostomy | 1 | 1995 | 1 | 0.030 |
Why?
|
| Chemokines | 1 | 2016 | 73 | 0.030 |
Why?
|
| Pseudarthrosis | 2 | 1992 | 5 | 0.030 |
Why?
|
| Somatostatin | 1 | 1995 | 55 | 0.030 |
Why?
|
| Pancreatic Ducts | 1 | 1995 | 26 | 0.030 |
Why?
|
| Hepacivirus | 1 | 1997 | 159 | 0.030 |
Why?
|
| Infant | 2 | 2001 | 3046 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2005 | 879 | 0.030 |
Why?
|
| Vero Cells | 2 | 2006 | 100 | 0.030 |
Why?
|
| Pregnancy | 2 | 2001 | 2894 | 0.030 |
Why?
|
| Laryngeal Neoplasms | 1 | 1996 | 89 | 0.030 |
Why?
|
| Kidney | 1 | 2002 | 1241 | 0.030 |
Why?
|
| North America | 1 | 2016 | 180 | 0.030 |
Why?
|
| Cell Differentiation | 2 | 2016 | 1458 | 0.030 |
Why?
|
| Receptors, CXCR3 | 1 | 2015 | 12 | 0.030 |
Why?
|
| Ipratropium | 1 | 1995 | 18 | 0.030 |
Why?
|
| Common Cold | 1 | 1995 | 13 | 0.030 |
Why?
|
| Luminescent Measurements | 1 | 2015 | 57 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2002 | 1195 | 0.030 |
Why?
|
| Lost to Follow-Up | 1 | 2015 | 12 | 0.030 |
Why?
|
| Leg | 1 | 1995 | 137 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 2 | 2014 | 1036 | 0.030 |
Why?
|
| Cholesterol | 1 | 2017 | 356 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2004 | 3362 | 0.030 |
Why?
|
| Alprostadil | 1 | 1994 | 25 | 0.030 |
Why?
|
| Clinical Coding | 1 | 2015 | 23 | 0.030 |
Why?
|
| Personnel, Hospital | 1 | 2015 | 30 | 0.030 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 1995 | 44 | 0.030 |
Why?
|
| Graft Survival | 2 | 1995 | 884 | 0.030 |
Why?
|
| Muromonab-CD3 | 1 | 1994 | 69 | 0.030 |
Why?
|
| Parenteral Nutrition, Total | 1 | 1994 | 41 | 0.030 |
Why?
|
| Robotic Surgical Procedures | 1 | 2020 | 267 | 0.030 |
Why?
|
| Embolism, Cholesterol | 1 | 1994 | 2 | 0.030 |
Why?
|
| Quality Control | 1 | 2015 | 117 | 0.030 |
Why?
|
| Age Factors | 1 | 2019 | 1851 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2016 | 679 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2015 | 187 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2015 | 69 | 0.030 |
Why?
|
| Popliteal Artery | 1 | 1994 | 27 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1995 | 78 | 0.030 |
Why?
|
| Administration, Oral | 2 | 1995 | 684 | 0.030 |
Why?
|
| Medical Records | 1 | 2015 | 119 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2007 | 782 | 0.030 |
Why?
|
| Relative Value Scales | 1 | 2014 | 9 | 0.030 |
Why?
|
| Base Sequence | 3 | 2011 | 2330 | 0.030 |
Why?
|
| Femoral Artery | 1 | 1994 | 81 | 0.030 |
Why?
|
| Enzyme Activation | 2 | 2006 | 692 | 0.030 |
Why?
|
| Fovea Centralis | 1 | 1994 | 21 | 0.030 |
Why?
|
| Arteriosclerosis | 1 | 1994 | 113 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 1995 | 233 | 0.030 |
Why?
|
| Pancreas | 1 | 1995 | 239 | 0.030 |
Why?
|
| Fixation, Ocular | 1 | 1994 | 48 | 0.030 |
Why?
|
| Dumping Syndrome | 1 | 2013 | 5 | 0.030 |
Why?
|
| Caregivers | 1 | 2015 | 151 | 0.030 |
Why?
|
| Avitaminosis | 1 | 2013 | 5 | 0.030 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 1995 | 105 | 0.030 |
Why?
|
| Social Support | 1 | 2015 | 193 | 0.030 |
Why?
|
| Risk Adjustment | 1 | 2014 | 39 | 0.030 |
Why?
|
| Survivors | 1 | 2015 | 226 | 0.030 |
Why?
|
| Saccades | 1 | 1994 | 69 | 0.030 |
Why?
|
| Frail Elderly | 1 | 2014 | 71 | 0.030 |
Why?
|
| Radiography, Interventional | 1 | 1995 | 150 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 582 | 0.030 |
Why?
|
| Chronic Disease | 1 | 1997 | 971 | 0.030 |
Why?
|
| Competency-Based Education | 1 | 2013 | 35 | 0.030 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 1994 | 138 | 0.030 |
Why?
|
| Cell Cycle | 2 | 2006 | 502 | 0.030 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 1994 | 112 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 999 | 0.030 |
Why?
|
| Foot Deformities | 1 | 1992 | 6 | 0.030 |
Why?
|
| Bone Lengthening | 1 | 1992 | 4 | 0.030 |
Why?
|
| Hyperplasia | 2 | 2009 | 148 | 0.030 |
Why?
|
| Umbilical Veins | 2 | 2004 | 46 | 0.030 |
Why?
|
| Radiography | 2 | 1992 | 813 | 0.030 |
Why?
|
| Contracture | 1 | 1992 | 18 | 0.030 |
Why?
|
| Motion Perception | 1 | 1994 | 105 | 0.030 |
Why?
|
| Multigene Family | 2 | 2005 | 202 | 0.030 |
Why?
|
| Diarrhea | 1 | 2013 | 182 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2016 | 579 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2014 | 219 | 0.030 |
Why?
|
| Gastric Mucosa | 1 | 2012 | 66 | 0.030 |
Why?
|
| Extracellular Space | 1 | 1992 | 90 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2012 | 124 | 0.030 |
Why?
|
| DNA, Complementary | 2 | 2004 | 393 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2012 | 268 | 0.030 |
Why?
|
| Schistosomiasis japonica | 1 | 1991 | 1 | 0.030 |
Why?
|
| Hand Deformities, Congenital | 1 | 1991 | 15 | 0.030 |
Why?
|
| Surgical Wound Infection | 1 | 2014 | 184 | 0.030 |
Why?
|
| Antibodies, Helminth | 1 | 1991 | 11 | 0.030 |
Why?
|
| Gastric Bypass | 1 | 2013 | 110 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2012 | 207 | 0.030 |
Why?
|
| Mesenteric Vascular Occlusion | 1 | 1991 | 18 | 0.030 |
Why?
|
| Parotid Diseases | 1 | 1991 | 5 | 0.030 |
Why?
|
| Infarction | 1 | 1991 | 26 | 0.030 |
Why?
|
| Prevalence | 2 | 2007 | 1239 | 0.030 |
Why?
|
| Pancreatitis | 1 | 2012 | 87 | 0.030 |
Why?
|
| Cholestasis, Extrahepatic | 1 | 1991 | 4 | 0.020 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 1991 | 70 | 0.020 |
Why?
|
| Vaccines, DNA | 1 | 2011 | 16 | 0.020 |
Why?
|
| Thrombocytopenia | 2 | 1990 | 183 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 1997 | 1981 | 0.020 |
Why?
|
| Perioperative Period | 1 | 2011 | 25 | 0.020 |
Why?
|
| Immunization, Secondary | 1 | 2011 | 30 | 0.020 |
Why?
|
| DNA Repair | 2 | 2004 | 356 | 0.020 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2011 | 64 | 0.020 |
Why?
|
| Tamoxifen | 1 | 1992 | 168 | 0.020 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2011 | 70 | 0.020 |
Why?
|
| Fibroblasts | 1 | 1994 | 729 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2011 | 369 | 0.020 |
Why?
|
| Cells, Cultured | 3 | 2004 | 2818 | 0.020 |
Why?
|
| Family | 1 | 2012 | 311 | 0.020 |
Why?
|
| Hematemesis | 1 | 2010 | 2 | 0.020 |
Why?
|
| Leukopenia | 1 | 1990 | 65 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2012 | 458 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2011 | 260 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2012 | 236 | 0.020 |
Why?
|
| Creatinine | 1 | 2011 | 338 | 0.020 |
Why?
|
| Drug Therapy, Combination | 2 | 2011 | 894 | 0.020 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2010 | 62 | 0.020 |
Why?
|
| Sepsis | 1 | 2014 | 306 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2010 | 159 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2014 | 574 | 0.020 |
Why?
|
| Education, Medical | 1 | 2013 | 233 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 2501 | 0.020 |
Why?
|
| Alanine Transaminase | 1 | 1990 | 73 | 0.020 |
Why?
|
| Disease Management | 1 | 2012 | 327 | 0.020 |
Why?
|
| Aspartate Aminotransferases | 1 | 1990 | 73 | 0.020 |
Why?
|
| Taxoids | 1 | 2010 | 129 | 0.020 |
Why?
|
| Bilirubin | 1 | 1990 | 125 | 0.020 |
Why?
|
| Depression | 1 | 2013 | 473 | 0.020 |
Why?
|
| Reference Standards | 1 | 2010 | 159 | 0.020 |
Why?
|
| RNA Polymerase II | 1 | 1990 | 55 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2011 | 384 | 0.020 |
Why?
|
| Forecasting | 1 | 2011 | 304 | 0.020 |
Why?
|
| Mastectomy | 1 | 1992 | 243 | 0.020 |
Why?
|
| Bile Duct Diseases | 1 | 2009 | 22 | 0.020 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2011 | 170 | 0.020 |
Why?
|
| Mucous Membrane | 1 | 2009 | 83 | 0.020 |
Why?
|
| Task Performance and Analysis | 1 | 2009 | 86 | 0.020 |
Why?
|
| Mammography | 1 | 1992 | 463 | 0.020 |
Why?
|
| Epithelial Cells | 2 | 2005 | 669 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2008 | 20 | 0.020 |
Why?
|
| Etanercept | 1 | 2008 | 32 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 307 | 0.020 |
Why?
|
| Nuclear Proteins | 2 | 2004 | 696 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2008 | 43 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2006 | 557 | 0.020 |
Why?
|
| Binding Sites | 3 | 2000 | 1098 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2008 | 88 | 0.020 |
Why?
|
| HeLa Cells | 2 | 2005 | 498 | 0.020 |
Why?
|
| Probability | 1 | 2009 | 355 | 0.020 |
Why?
|
| Stem Cells | 1 | 2011 | 351 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 1991 | 0.020 |
Why?
|
| Metaplasia | 1 | 2007 | 37 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2011 | 425 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2013 | 1621 | 0.020 |
Why?
|
| Acetylation | 1 | 2007 | 121 | 0.020 |
Why?
|
| Oncolytic Viruses | 1 | 2007 | 23 | 0.020 |
Why?
|
| Cell Line | 4 | 1993 | 2468 | 0.020 |
Why?
|
| Quinoxalines | 1 | 2007 | 50 | 0.020 |
Why?
|
| Sirtuins | 1 | 2007 | 45 | 0.020 |
Why?
|
| Quality of Life | 1 | 2015 | 1585 | 0.020 |
Why?
|
| Luciferases | 1 | 2007 | 118 | 0.020 |
Why?
|
| Cellular Senescence | 1 | 2007 | 94 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2009 | 444 | 0.020 |
Why?
|
| Mass Screening | 1 | 1992 | 618 | 0.020 |
Why?
|
| Genetic Engineering | 1 | 2007 | 114 | 0.020 |
Why?
|
| Parathyroidectomy | 1 | 2007 | 78 | 0.020 |
Why?
|
| Imidazoles | 1 | 2007 | 162 | 0.020 |
Why?
|
| Antineoplastic Protocols | 1 | 2006 | 9 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2009 | 379 | 0.020 |
Why?
|
| Stomatitis | 1 | 2006 | 30 | 0.020 |
Why?
|
| Genes, Neoplasm | 1 | 2006 | 37 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2008 | 456 | 0.020 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2007 | 153 | 0.020 |
Why?
|
| Aging | 1 | 2011 | 691 | 0.020 |
Why?
|
| Parathyroid Hormone | 1 | 2007 | 218 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2007 | 329 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2010 | 484 | 0.020 |
Why?
|
| Genes, MDR | 1 | 2005 | 7 | 0.020 |
Why?
|
| Herpes Simplex | 1 | 2007 | 202 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 2009 | 380 | 0.020 |
Why?
|
| Tumor Necrosis Factors | 1 | 2005 | 14 | 0.020 |
Why?
|
| Wounds, Stab | 1 | 1985 | 9 | 0.020 |
Why?
|
| Genes, ras | 1 | 2006 | 96 | 0.020 |
Why?
|
| Cholecystectomy | 1 | 1985 | 18 | 0.020 |
Why?
|
| Flavonoids | 1 | 2006 | 85 | 0.020 |
Why?
|
| Cornified Envelope Proline-Rich Proteins | 1 | 2005 | 6 | 0.020 |
Why?
|
| Cell Death | 1 | 2006 | 256 | 0.020 |
Why?
|
| Abdominal Injuries | 1 | 1985 | 39 | 0.020 |
Why?
|
| GATA6 Transcription Factor | 1 | 2005 | 13 | 0.020 |
Why?
|
| Palliative Care | 1 | 2007 | 257 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2005 | 102 | 0.020 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2005 | 90 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2005 | 265 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2005 | 192 | 0.020 |
Why?
|
| Wounds, Nonpenetrating | 1 | 1985 | 92 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2005 | 370 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2005 | 303 | 0.020 |
Why?
|
| Integrin alphaV | 1 | 2004 | 4 | 0.020 |
Why?
|
| Infrared Rays | 1 | 2004 | 17 | 0.020 |
Why?
|
| DNA-Activated Protein Kinase | 1 | 2004 | 16 | 0.020 |
Why?
|
| Rabbits | 1 | 2005 | 636 | 0.020 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2004 | 17 | 0.020 |
Why?
|
| Integrin beta1 | 1 | 2004 | 33 | 0.020 |
Why?
|
| Wounds, Gunshot | 1 | 1985 | 71 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2004 | 74 | 0.020 |
Why?
|
| Acetylcysteine | 1 | 2004 | 69 | 0.020 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2004 | 52 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2004 | 164 | 0.010 |
Why?
|
| Rad51 Recombinase | 1 | 2004 | 80 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2008 | 977 | 0.010 |
Why?
|
| Clinical Chemistry Tests | 1 | 2003 | 11 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2005 | 1106 | 0.010 |
Why?
|
| Pheochromocytoma | 1 | 2003 | 49 | 0.010 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2003 | 42 | 0.010 |
Why?
|
| Cell Division | 1 | 2004 | 696 | 0.010 |
Why?
|
| Calcium | 1 | 2007 | 1156 | 0.010 |
Why?
|
| CHO Cells | 1 | 2002 | 187 | 0.010 |
Why?
|
| Plasmids | 1 | 2003 | 287 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2004 | 279 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2004 | 353 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2002 | 56 | 0.010 |
Why?
|
| Cell Hypoxia | 1 | 2003 | 164 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 1801 | 0.010 |
Why?
|
| Cathepsin L | 1 | 2001 | 7 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 2004 | 439 | 0.010 |
Why?
|
| Cathepsins | 1 | 2001 | 21 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2002 | 154 | 0.010 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2001 | 47 | 0.010 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2003 | 151 | 0.010 |
Why?
|
| Collagenases | 1 | 2001 | 39 | 0.010 |
Why?
|
| Liver | 2 | 2001 | 1230 | 0.010 |
Why?
|
| Cricetinae | 1 | 2002 | 560 | 0.010 |
Why?
|
| Constriction | 1 | 2001 | 27 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2004 | 388 | 0.010 |
Why?
|
| Cysteine Endopeptidases | 1 | 2001 | 87 | 0.010 |
Why?
|
| Mouth Mucosa | 1 | 2001 | 67 | 0.010 |
Why?
|
| Bleomycin | 1 | 1981 | 98 | 0.010 |
Why?
|
| Adenovirus E1B Proteins | 1 | 2001 | 1 | 0.010 |
Why?
|
| Isocoumarins | 1 | 2000 | 7 | 0.010 |
Why?
|
| Receptors, CCR5 | 1 | 2000 | 17 | 0.010 |
Why?
|
| Radiation Tolerance | 1 | 2002 | 168 | 0.010 |
Why?
|
| Methotrexate | 1 | 1981 | 249 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2002 | 222 | 0.010 |
Why?
|
| Viremia | 1 | 2001 | 54 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2000 | 188 | 0.010 |
Why?
|
| Receptors, CXCR4 | 1 | 2000 | 44 | 0.010 |
Why?
|
| Laminin | 1 | 2000 | 85 | 0.010 |
Why?
|
| Glycosylation | 1 | 2000 | 129 | 0.010 |
Why?
|
| Mastectomy, Radical | 1 | 2000 | 10 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2000 | 224 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2000 | 121 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2001 | 504 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 2000 | 408 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 1996 | 3030 | 0.010 |
Why?
|
| Proteins | 1 | 2005 | 777 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2000 | 364 | 0.010 |
Why?
|
| Collagen | 1 | 2000 | 269 | 0.010 |
Why?
|
| Kinetics | 2 | 1993 | 1513 | 0.010 |
Why?
|
| Tegafur | 1 | 1998 | 17 | 0.010 |
Why?
|
| Uracil | 1 | 1998 | 72 | 0.010 |
Why?
|
| Amino Acid Sequence | 2 | 1992 | 2062 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2001 | 408 | 0.010 |
Why?
|
| Software | 1 | 2001 | 654 | 0.010 |
Why?
|
| Nausea | 1 | 1998 | 175 | 0.010 |
Why?
|
| Environmental Pollution | 1 | 1996 | 13 | 0.010 |
Why?
|
| Genetic Variation | 2 | 1993 | 1351 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 1999 | 819 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 1995 | 63 | 0.010 |
Why?
|
| Methylene Blue | 1 | 1995 | 18 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1994 | 66 | 0.010 |
Why?
|
| Global Health | 1 | 1996 | 193 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 1995 | 66 | 0.010 |
Why?
|
| Methylprednisolone | 1 | 1994 | 66 | 0.010 |
Why?
|
| Food, Formulated | 1 | 1994 | 24 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 1994 | 94 | 0.010 |
Why?
|
| Burns, Chemical | 1 | 1994 | 12 | 0.010 |
Why?
|
| Nebulizers and Vaporizers | 1 | 1995 | 55 | 0.010 |
Why?
|
| Granuloma | 1 | 1995 | 65 | 0.010 |
Why?
|
| Nasal Mucosa | 1 | 1995 | 186 | 0.010 |
Why?
|
| Esophageal Perforation | 1 | 1994 | 18 | 0.010 |
Why?
|
| Contraindications | 1 | 1994 | 72 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 1995 | 81 | 0.010 |
Why?
|
| Energy Intake | 1 | 1994 | 98 | 0.010 |
Why?
|
| Biopsy | 1 | 1998 | 1163 | 0.010 |
Why?
|
| Azathioprine | 1 | 1994 | 125 | 0.010 |
Why?
|
| Topotecan | 1 | 1994 | 45 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1994 | 145 | 0.010 |
Why?
|
| Esophagus | 1 | 1994 | 102 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 1994 | 129 | 0.010 |
Why?
|
| Cyclosporine | 1 | 1994 | 234 | 0.010 |
Why?
|
| Retroviridae | 1 | 1994 | 79 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 1994 | 156 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 1994 | 152 | 0.010 |
Why?
|
| Diet | 1 | 1996 | 443 | 0.010 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 1992 | 28 | 0.010 |
Why?
|
| Bone Wires | 1 | 1992 | 12 | 0.010 |
Why?
|
| Achondroplasia | 1 | 1992 | 8 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1992 | 155 | 0.010 |
Why?
|
| Immunoglobulin Idiotypes | 1 | 1992 | 12 | 0.010 |
Why?
|
| Antigen-Antibody Complex | 1 | 1992 | 87 | 0.010 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 1992 | 96 | 0.010 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 1992 | 131 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1993 | 646 | 0.010 |
Why?
|
| Immunoglobulin Variable Region | 1 | 1992 | 109 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 1993 | 227 | 0.010 |
Why?
|
| Neoplasms, Second Primary | 1 | 1995 | 252 | 0.010 |
Why?
|
| Genes, Immunoglobulin | 1 | 1992 | 111 | 0.010 |
Why?
|
| Syndactyly | 1 | 1991 | 12 | 0.010 |
Why?
|
| Philippines | 1 | 1991 | 23 | 0.010 |
Why?
|
| Antigens, Helminth | 1 | 1991 | 22 | 0.010 |
Why?
|
| Cross Reactions | 1 | 1991 | 106 | 0.010 |
Why?
|
| Remission, Spontaneous | 1 | 1991 | 53 | 0.010 |
Why?
|
| Gene Rearrangement | 1 | 1992 | 170 | 0.010 |
Why?
|
| HLA-DR Antigens | 1 | 1991 | 61 | 0.010 |
Why?
|
| Ovum | 1 | 1991 | 58 | 0.010 |
Why?
|
| Edema | 1 | 1991 | 71 | 0.010 |
Why?
|
| China | 1 | 1991 | 228 | 0.010 |
Why?
|
| Culture Techniques | 1 | 1971 | 91 | 0.010 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 1991 | 70 | 0.010 |
Why?
|
| Liver Regeneration | 1 | 1971 | 32 | 0.010 |
Why?
|
| Herpesvirus 4, Human | 1 | 1991 | 114 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 1991 | 93 | 0.010 |
Why?
|
| Aorta, Thoracic | 1 | 1991 | 165 | 0.010 |
Why?
|
| Transcription Factor TFIIA | 1 | 1990 | 2 | 0.010 |
Why?
|
| Transcription Factor TFIID | 1 | 1990 | 3 | 0.010 |
Why?
|
| Templates, Genetic | 1 | 1990 | 34 | 0.010 |
Why?
|
| Ischemia | 1 | 1991 | 243 | 0.010 |
Why?
|
| Protein Binding | 1 | 1993 | 1456 | 0.010 |
Why?
|
| Ultrasonography | 1 | 1991 | 695 | 0.010 |
Why?
|
| Temperature | 1 | 1990 | 396 | 0.010 |
Why?
|
| Intestines | 1 | 1991 | 411 | 0.010 |
Why?
|
| Neutropenia | 1 | 1981 | 215 | 0.000 |
Why?
|
| Vesicular stomatitis Indiana virus | 1 | 1971 | 16 | 0.000 |
Why?
|
| Hypophysectomy | 1 | 1971 | 27 | 0.000 |
Why?
|
| Thymidine | 1 | 1971 | 59 | 0.000 |
Why?
|
| Tritium | 1 | 1971 | 133 | 0.000 |
Why?
|
| Methods | 1 | 1971 | 152 | 0.000 |
Why?
|
| Carbon Isotopes | 1 | 1971 | 76 | 0.000 |
Why?
|
| Bromodeoxyuridine | 1 | 1971 | 57 | 0.000 |
Why?
|
| Haploidy | 1 | 1971 | 31 | 0.000 |
Why?
|
| Prolactin | 1 | 1971 | 88 | 0.000 |
Why?
|
| Growth Hormone | 1 | 1971 | 97 | 0.000 |
Why?
|
| Leiomyosarcoma | 1 | 1971 | 40 | 0.000 |
Why?
|
| Interferons | 1 | 1971 | 133 | 0.000 |
Why?
|
| Hybridization, Genetic | 1 | 1971 | 104 | 0.000 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 1971 | 124 | 0.000 |
Why?
|
| Testicular Neoplasms | 1 | 1971 | 105 | 0.000 |
Why?
|
| Thyroxine | 1 | 1971 | 344 | 0.000 |
Why?
|
| Selection, Genetic | 1 | 1971 | 502 | 0.000 |
Why?
|
| Insulin | 1 | 1971 | 1160 | 0.000 |
Why?
|
| Ovarian Neoplasms | 1 | 1971 | 744 | 0.000 |
Why?
|